Posted by Michael Wonder on 09 Nov 2018
NICE nod for Jazz’ AML chemo
8 November 2018 - Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of NICE for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias.
In a Final Appraisal Determination the Institute has approved funding for the drug when used to treat adults with newly diagnosed, therapy-related t-acute myeloid leukaemia (AML) or AML with myelodysplasia-related changes (AML-MRC), two types of secondary AML.
“This is the first new chemotherapy in forty years for adults with specific types of newly diagnosed secondary AML, a particularly aggressive cancer that typically affects older people and has a high mortality rate,” said Dr Nigel Russell, Professor of Haematology, Faculty of Medicine & Health Sciences at the University of Nottingham.
